New approaches to treating Alzheimer's disease.
To date, no truly efficacious drugs for Alzheimer's disease (AD) have been developed; moreover, all new anti-AD drugs developed since 2003 have failed. To succeed where previous ones have failed in drug development, new approaches for AD therapy are needed. Here we discuss the potential application of network medicine as a new approach to AD treatment. Unlike traditional approaches focused on a single target/pathway, network medicine targets and restores disease-disrupted networks through simultaneous modulation of numerous proteins (targets)/pathways involved in AD pathogenesis. We consider several drug candidates under development for AD therapy, including Keap1-Nrf2 regulators, endogenous neurogenic agents, and hypoxia-inducible factor 1 (HIF-1) activators. These drug candidates are multi-target ligands with the potential to further develop as network medicines, since they act as master regulators to initiate a broad range of cellular defense mechanisms/cytoprotective genes that exert their efficacy in a holistic way. We also explore their diverse mechanisms of action and potential disease-modifying effects, which may have profound implications for drug discovery.
Department of Medicinal Chemistry, Intra-cellular Therapies Inc., New York, NY, USA.
Hailin
H
Zheng
Department of Organic Chemistry, Weizmann Institute of Science, Rehovot, Israel.
Mati
M
Fridkin
Abital Pharma Pipeline Ltd., Tel Aviv, Israel.
Moussa
M
Youdim
AChE-MAO-A/B inhibitor; Alzheimer’s disease; HIF-1 activator; Keap1–Nrf2 regulator; M30; neurogenic agents